[ad_1]
-
Released during Liver Health Awareness Month and based primarily on HCP market research, Salix Pharmaceuticals’ annual Liver Health Trends Report found that more than a third of gastroenterologists surveyed had seen an increase in patient hospitalizations due to cirrhosis in the last year
-
The report states that reimbursement challenges are negatively impacting the management of chronic liver disease as reported by survey respondents
LAVAL, QC, October 12, 2022 /CNW/ — Salix Pharmaceuticals (“Salix”), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today launched Salix Annual Report on Trends in Liver Health, Second Edition with the latest information on chronic liver disease (CKD) care and findings, which include continued increases in hospitalizations and mortality from CKD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CKD , cirrhosis and its complications.
The trends report, which is based on a survey of 400 healthcare providers (HCPs) who treat patients with CLD, qualitative interviews with HCPs and secondary research from peer-reviewed publications, reveals gaps in the uptake of national treatment guidelines, particularly among doctors from primary care providers (PCPs). Perceived problems with payer coverage (due to the complexity of prior authorization/denials) and high out-of-pocket costs/unaffordability were found to be the leading factors negatively impacting treatment initiation or causing treatment discontinuations.
“Salix is committed to providing resources that inform, educate and help healthcare providers improve care for people living with chronic liver disease, cirrhosis and complications such as hepatic encephalopathy,” they said Nicholas Cael, Vice President, GI Marketing, Salix. “This year’s report points to a continued rise in deaths from chronic liver disease and cirrhosis, now outpacing diabetes or stroke among those aged 25-541. It is clear from both patient and provider research that there is a real need for more education and engagement resources to support the management of CLD. This is our hope Salix Annual report on trends in liver health will raise awareness of this growing public health concern, help close the knowledge gap, and provide tools for healthcare providers that can improve disease identification and management.”
The Annual Salix Liver Health Trends Report is being released in October during Liver Health Awareness Month as part of an effort to provide healthcare providers with the most up-to-date information about liver disease.
“The Global Liver Institute welcomes the publication of this year’s Annual report on trends in liver health which will help better understand the personal and societal impact of chronic liver disease and potentially help address its underdiagnosis and undertreatment among the estimated 4.5 million US adults living with the disease2,” said Donna R. CryerJD, Founder and CEO, Global Liver Institute.
Complete findings from Salix’s Annual report on trends in liver health as well as health care provider resources to help identify and manage patients with CLD and cirrhosis can be viewed at LiverHEalthNow.com.
Selected findings from the report include:
-
34% of gastroenterologists surveyed reported an increase in patient hospitalizations due to alcoholic liver cirrhosis in the past year
-
38% of respondents did not know and/or could not name national guidelines for the management of CLD
-
55% of PCPs and 49% of nurse practitioners/physician assistants in the study did not feel comfortable treating overt hepatic encephalopathy (OHE) and sought consultation
-
50% of surveyed providers reported that a patient’s ability to pay out-of-pocket costs was very or extremely important to CLD patient outcomes
About the methodology behind the annual Liver Health Trends Report
The Annual report on trends in liver health on chronic liver disease (CLD) includes information gathered from an online survey, qualitative telephone interviews and secondary research from peer-reviewed publications. An independent third-party recruitment firm invited over 400 healthcare providers to participate in this research project during May 2022. Provider participation (N=400) in the study required individuals to be active in clinical practice and treat more than 4 CLD patients per year and consisted of the following subgroups: 100 community gastroenterologists, 100 institutional specialists, 100 primary care physicians assistance (PCPs) and 100 nurse practitioners/physician assistants (NPs/PAs). In addition to completing the online survey, 15 physicians and 5 NP/PAs also completed in-depth telephone interviews (Table 1). Quotes from in-depth interviews in this report represent the views of those respondents. As for the online survey, data analysis was performed using QPSMR data analysis software.
The report seeks to be representative of the lived experience of all physician segments and the diversity that exists within United States in terms of patient management and the economic and social factors that influence the management of patients with CLD. Due to the limitations of this report, not all findings may be generalized to larger CLD provider and patient populations. Furthermore, this report does not contain all the questions asked in the survey and in-depth interviews.
Secondary research of peer-reviewed publications
A secondary search was conducted using Google and PubMed searches to identify relevant peer-reviewed publications and sources as noted in the report. In addition, treatment utilization and claims data were obtained from IQVIA. Secondary research may not reflect all published data. A systematic review was not performed. While the included publications were peer-reviewed, this secondary research generally was not.
To increase awareness and knowledge of CLD and HE, Salix also offers other online resources including:
-
UnderstandingHE.com: offers patients/caregivers HE information and resources on how to work with their healthcare provider to help manage the disease, a complication of cirrhosis
-
UnseenEpisodes.com: offers healthcare providers information on the unseen aspects and considerations in managing patients with HE
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world engaged in the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients’ lives and arm healthcare providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to healthcare providers in the US through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is based in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and contact us at Twitter and LinkedIn.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our healthcare products. We develop, manufacture and market a range of products primarily in the fields of gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading enduring brands, we deliver on our commitments as we build an innovative company dedicated to advancing global health.
Forward-looking statements
This news release may contain forward-looking statements about the Company’s future performance, which generally can be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “may,” “would,” “can,” “believes,” “subject to” and variations or similar expressions. These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Company’s overall business, including those more fully described in the Company’s most recent Annual Report on Form 10-K and detailed since time in the Company’s other filings with the U.S. Securities and Exchange Commission and Canadian securities regulators, which factors are incorporated herein by reference.
©2022 Salix Pharmaceuticals or its affiliates.
SAL.0112.USA.22
1 Xu JQ, Murphy SL, Kochanek KD, Arias E. Deaths: final data for 2019. Natl Vital Stat Rep. 70 (8). Hyattsville, MD: National Center for Health Statistics. 2021
2 Centers for Disease Control and Prevention. Chronic liver disease and cirrhosis. Access September 9, 2022. https://www.cdc.gov/nchs/fastats/liver-disease.htm
Gianna Scalera
salixcommunications@salix.com
(908) 541-2110
View original content for multimedia download: https://www.prnewswire.com/news-releases/salix-pharmaceuticals-releases-liver-health-annual-trends-report-underscoring-challenges-in-caring-for-growing- chronic-liver-disease-and-cirrhosis-patient-population-301646728.html
SOURCE Bausch Health Companies Inc.
View original media download content: http://www.newswire.ca/en/releases/archive/October2022/12/c2100.html
[ad_2]
Source link